Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • Editorial Board
    • Meet the Editors
    • Editorial Manifesto
    • Impact Factor
    • Journal History
    • General Statistics
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • Circulation Research Profiles
    • Trainees & Young Investigators
    • Research Around the World
    • News & Views
    • The NHLBI Page
    • Viewpoints
    • Compendia
    • Reviews
    • Recent Review Series
    • Profiles in Cardiovascular Science
    • Leaders in Cardiovascular Science
    • Commentaries on Cutting Edge Science
    • AHA/BCVS Scientific Statements
    • Abstract Supplements
    • Circulation Research Classics
    • In This Issue Archive
    • Anthology of Images
  • Resources
    • Online Submission/Peer Review
    • Why Submit to Circulation Research
    • Instructions for Authors
    • → Article Types
    • → Manuscript Preparation
    • → Submission Tips
    • → Journal Policies
    • Circulation Research Awards
    • Image Gallery
    • Council on Basic Cardiovascular Sciences
    • Customer Service & Ordering Info
    • International Users
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Impact Factor 13.965
  • Facebook
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Circulation Research

  • My alerts
  • Sign In
  • Join

  • Impact Factor 13.965
  • Facebook
  • Twitter
  • Home
  • About this Journal
    • Editorial Board
    • Meet the Editors
    • Editorial Manifesto
    • Impact Factor
    • Journal History
    • General Statistics
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • Circulation Research Profiles
    • Trainees & Young Investigators
    • Research Around the World
    • News & Views
    • The NHLBI Page
    • Viewpoints
    • Compendia
    • Reviews
    • Recent Review Series
    • Profiles in Cardiovascular Science
    • Leaders in Cardiovascular Science
    • Commentaries on Cutting Edge Science
    • AHA/BCVS Scientific Statements
    • Abstract Supplements
    • Circulation Research Classics
    • In This Issue Archive
    • Anthology of Images
  • Resources
    • Online Submission/Peer Review
    • Why Submit to Circulation Research
    • Instructions for Authors
    • → Article Types
    • → Manuscript Preparation
    • → Submission Tips
    • → Journal Policies
    • Circulation Research Awards
    • Image Gallery
    • Council on Basic Cardiovascular Sciences
    • Customer Service & Ordering Info
    • International Users
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
In This Issue

In This Issue

Ruth Williams
Download PDF
https://doi.org/10.1161/RES.0000000000000020
Circulation Research. 2014;114:1069
Originally published March 27, 2014
Ruth Williams
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Info & Metrics

Jump to

  • Article
    • Activated Platelet Targeted Fibrinolysis (p 1083)
    • O-GlcNAcylation and Vascular Calcification (p 1094)
    • CPVT CaM Mutants and RyR2 Channels (p 1114)
  • Figures & Tables
  • Info & Metrics
  • eLetters
Loading

Activated Platelet Targeted Fibrinolysis (p 1083)

Figure1
  • Download figure
  • Open in new tab
  • Download powerpoint

Wang et al develop a low dose, low risk thrombolytic fusion protein for busting blood clots.

Thrombolytic drugs such as tissue plasminogen activator are used to breakdown blood clots in the event of a heart attack or stroke, but because these drugs act systemically, they carry a high risk of causing excessive bleeding. If such drugs could be targeted specifically to blood clots, it would both increase their potency and decrease their associated bleeding risk. Wang and colleagues therefore created a new fusion protein between a plasminogen activator and an antibody that specifically targets clot-initiating activated platelets. They found that the fusion protein inhibited platelet aggregation in culture, and maintained blood flow velocity more effectively than an equivalent dose of commercial untargeted plasminogen activator when given to mice that were induced to develop thrombi. A high dose of the commercial drug gave results similar to the fusion protein, but it dramatically increased bleeding times following tail transections. Based on the ability to the fusion protein to breakdown clots at a lower dose, without drastically increasing bleeding risk, Wang and colleagues suggest that such antibody targeted clot-busting strategies might be used not only as thrombolytic agents but also as a preventative treatment in patients at high risk of thrombosis.

O-GlcNAcylation and Vascular Calcification (p 1094)

Figure2
  • Download figure
  • Open in new tab
  • Download powerpoint

Heath et al find a causative link between O-GlcNAcylation and vascular calcification in diabetes.

Vascular calcification is a common complication of diabetes and is associated with an increased risk of life-threatening cardiovascular events. Determining how calcification occurs and how to prevent it are therefore major goals of current diabetes research. Previous work has shown that proteins in the calcified blood vessels of patients with diabetes exhibit high levels of a post-translational modification called O-GlcNAcylation, in which N-acetylglucosamine moieties are linked to serine or threonine residues. But whether and how O-GlcNAcylation might cause calcification was unknown. Heath and colleagues, therefore, experimentally induced O-GlcNAcylation in mouse vascular smooth muscle cells (VSMCs) and in the blood vessels of diabetic mice and found that both were subject to increased calcification. Furthermore, they found that O-GlcNAcylation directly modified AKT, a protein kinase known to promote VSMC calcification. Mutational analysis revealed that the O-GlcNAcylation occurred on threonine 430 and 479 of AKT, which in turn promoted phosphorylation of serine 473; thereby enhancing AKT activity and activating the downstream calcification pathway. Blocking O-GlcNAcylation of AKT may therefore be a novel strategy for preventing vessel calcification in diabetes, say the authors.

CPVT CaM Mutants and RyR2 Channels (p 1114)

Figure3
  • Download figure
  • Open in new tab
  • Download powerpoint

Hwang et al investigate how different calmodulin mutants affect ryanodine receptor 2 calcium channels.

Calmodulin (CaM) is a calcium-binding protein that regulates several cell functions, including calcium sensing and calcium release from intracellular stores. Mutations in the CaM gene have been linked to cardiac arrhythmia, although different mutations cause different types of irregularity. For example, two specific CaM mutants, associated with stress-induced polymorphic ventricular tachycardia, are referred to as CPVT-CaMs, while another three associated with long QT syndrome are referred to as LQTS-CaMs. In the heart, wild type CaM binds to and inhibits the sarcoplasmic reticulum calcium channel ryanodine receptor 2 (RyR2), reducing the frequency of calcium release. Hwang and colleagues have now discovered that CPVT-CaMs bind with higher efficiency to RyR2 and that they increase rather than reduce the frequency of calcium release. LQTS-CaMs on the other hand tend not to affect RyR2 function, suggesting an alternative mechanism of arrhythmogenesis. CPVT-CaMs dysregulated RyR2 even in the presence of an 8-fold excess of wild type protein. This potency of the mutant proteins explains their dominant phenotypic effects. Altogether the results explain the distinct types of arrhythmia caused by the different CaM mutations, which in turn may help in the development of appropriate treatment strategies for carriers of the mutations.

  • © 2014 American Heart Association, Inc.
View Abstract
Back to top
Previous ArticleNext Article

This Issue

Circulation Research
March 28, 2014, Volume 114, Issue 7
  • Table of Contents
Previous ArticleNext Article

Jump to

  • Article
    • Activated Platelet Targeted Fibrinolysis (p 1083)
    • O-GlcNAcylation and Vascular Calcification (p 1094)
    • CPVT CaM Mutants and RyR2 Channels (p 1114)
  • Figures & Tables
  • Info & Metrics

Article Tools

  • Print
  • Citation Tools
    In This Issue
    Ruth Williams
    Circulation Research. 2014;114:1069, originally published March 27, 2014
    https://doi.org/10.1161/RES.0000000000000020

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  •  Download Powerpoint
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Circulation Research.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    In This Issue
    (Your Name) has sent you a message from Circulation Research
    (Your Name) thought you would like to see the Circulation Research web site.
  • Share on Social Media
    In This Issue
    Ruth Williams
    Circulation Research. 2014;114:1069, originally published March 27, 2014
    https://doi.org/10.1161/RES.0000000000000020
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Circulation Research

  • About Circulation Research
  • Editorial Board
  • Instructions for Authors
  • Abstract Supplements
  • AHA Statements and Guidelines
  • Permissions
  • Reprints
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Editorial Office Address:
3355 Keswick Rd
Main Bldg 103
Baltimore, MD 21211
CircRes@circresearch.org

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured